THALES
2.6.2021 09:02:13 CEST | Business Wire | Press release
Despite being over a year into remote working and looking ahead to likely shifts to hybrid remote/in-office working models, four fifths (82%) of businesses still remain concerned about the security risks of employees working remotely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005100/en/
This is just one of the key insights from the 2021 Thales Global Data Threat Report, a commissioned study conducted by 451 Research, part of S&P Global Market Intelligence, which reveals that managing security risks is undoubtedly getting more challenging, with nearly half (47%) of businesses seeing an increase in the volume, severity, and/or scope of cyber-attacks in the past 12 months.
Attacks On The Rise
In fact, of those who have ever experienced a breach, two in five (41%) happened in the last year. This number has nearly doubled from 21% in 2019, marking a significant shift in the threat posed.
Globally, malware (54%) is the leading source of security attacks, followed by ransomware (48%), and phishing (41%). Yet, when it comes to how attacks occur, the message is clear: internal threats and human error are still of great concern to industry. A third of businesses stated that malicious insiders (35%) and human error (31%) are the greatest risks to them, followed by external attackers (22%).
Despite the increased risk remote working has posed to enterprises throughout the pandemic, nearly half (46%) of businesses report that their security infrastructure was not prepared to handle the risks caused by Covid-19. In fact, only one in five (20%) of organisations believe it was very prepared.
Multiple Industries at Risk
This lack of protection is affecting some industries more than others it seems, with just under two thirds (61%) of retailers surveyed experiencing a breach or failing an audit involving data and applications stored in the cloud in the past year – the most of any industry surveyed. Over half of organisations in the legal (57%), call centre (55%), transportation (54%), and telecommunications (52%) sectors also suffered the same fate in the last 12 months.
Multicloud Complexity Increases Risks
As increases in attacks continue, businesses are turning to the cloud to store their data in this digital-first world. Half (50%) of businesses report that more than 40% of their data is stored in external cloud environments. Despite this, only 17% of businesses have encrypted at least half of their sensitive data stored in the cloud. On top of this, complexity is an increasing issue, with many respondents now using at least two PaaS (Platform as a Service) providers (45%) and/or two IaaS providers (Infrastructure as a Service). A quarter (27%) of businesses are currently using more than 50 SaaS (Software as a Service) apps.
Sebastien Cano, Senior Vice President for Cloud Protection and Licensing activities at Thales comments: “Teams across the globe have faced huge security challenges over the last year as companies accelerated their digital transformation and cloud adoption initiatives. When migrating to multicloud solutions, data management can quickly spiral out of control. Organisations not only risk losing track of where their data is stored across multicloud environments but also fail to protect sensitive data in the cloud. With once unprecedented amounts of data now being used and stored in the cloud, it is vital that businesses deploy a robust security strategy based on data discovery, protection and control.”
Future Challenges and the Road Ahead
Companies are recognising the issues they are facing and are attempting to address them with Zero Trust strategies. More than three quarters (76%) of respondents’ cloud strategy reportedly rely to some degree on Zero Trust security. Almost half (44%) of respondents selected Zero Trust network access (ZTNA)/software-defined perimeter (SDP) as the leading technology to invest in during the pandemic. This was followed by cloud-based access management (42%) and conditional access (41%). In fact, a third (30%) of global respondents claim to have a formal Zero Trust strategy and, interestingly, those with a formal Zero Trust strategy are less likely to also report having been breached.
However, despite businesses making moves to stop current threats, worries are growing about future challenges on the horizon. Looking ahead, 85% of global respondents are concerned about the security threats of quantum computing, a threat arguably exacerbated by the increasing complexity of cloud environments.
Eric Hanselman, Chief Analyst at 451 Research, part of S&P Global Market Intelligence added: “The native controls and protections available in cloud environments address a set of necessary capabilities, but they’re often insufficient to deliver effective protections for sensitive data and workloads, especially when it comes to compliance with regulations such as GDPR and the implications of the Schrems II ruling. Organisations need to increase their use of encryption and ensure they take full advantage of encryption’s benefits by controlling the secrets that protect their data through BYOK (Bring Your Own Key), HYOK (Hold Your Own Key) or BYOE (Bring Your Own Encryption) approaches. Organisations also need to make internal changes to ensure that personnel at all levels understand the security challenges and to properly align investment priorities. Senior executives need to obtain a more complete understanding of the levels of risk and attack activity that their front-line staff are experiencing.”
Thales and 451 Research will discuss the findings in more detail during its upcoming Crypto Summit on 16 June 2021. To join, please visit the registration page .
About the 2021 Thales Global Data Threat Report
The 2021 Thales Global Data Threat Report was based on a global 451 Research survey commissioned by Thales of more than 2,600 executives with responsibility for or influence over IT and data security. Respondents were from 16 countries: Australia, Brazil, France, Germany, Hong Kong, India, Japan, Mexico, Netherlands, New Zealand, Singapore, South Korea, Sweden, the United Arab Emirates, the United Kingdom, and the United States. Organisations represented a range of industries, with a primary emphasis on healthcare, financial services, retail, technology, and federal government. Job titles ranged from C-level executives including CEO, CFO, Chief Data Officer, CISO, Chief Data Scientist, and Chief Risk Officer, to SVP/VP, IT Administrator, Security Analyst, Security Engineer, and Systems Administrator. Respondents represented a broad range of organizational sizes, with the majority ranging from 500 to 10,000 employees. The survey was conducted in January - February 2021.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005100/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
